You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Eloralintide
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling.
Is eloralintide a selective amylin receptor agonist?
Eloralintide acts as a selective amlin receptor agonist, It is currently in phase 2 studied for the treatment of obesity.
Selective Amylin Agonist
Eloralintide has selectivity for amylin-1 receptors (AMY1R) over amylin-3 receptors (AMY3R) or calcitonin receptors (CTR) in human assays (see In Vitro Receptor Binding Affinity – Fold Difference in Ki).1
Eloralintide exhibits approximately 12-fold greater potency for AMY1R and approximately 11-fold greater potency for AMY3R compared with CTR in humans.1
Peptide |
AMY1R vs CTR |
AMY-3R vs CTR |
AMY1R vs AMY3R |
In human receptors |
|||
Eloralintide (human receptor) |
8.1 |
1.1 |
7.5 |
Cagrilintide (human receptor) |
2.5 |
1.6 |
1.6 |
In rat receptors |
|||
Eloralintide |
109.4 |
32.7 |
3.3 |
Cagrilintide |
1.2 |
2.8 |
0.4 |
Abbreviations: AMY1R = amylin 1 receptor; AMY3R = human amylin 3 receptor; CTR = human calcitonin receptor; Ki = inhibition constant.
Rat models suggest that selectively targeting AMY1R or AMY3R compared with CTR, may
- reduce food intake
- improve body weight loss, and
- improve gastrointestinal tolerability.1
Further research is needed to determine the functional significance of selectivity in humans.
References
1Briere DA, Qu H, Lansu K, et al. Eloralintide (LY3841136), a novel amylin receptor agonist for the treatment of obesity: from discovery to clinical proof of concept. 2025:102;102271. https://doi.org/10.1016/j.molmet.2025.102271
Date of Last Review: November 03, 2025